Journal of Hematology & Oncology (Jul 2025)
Circular RNA signature of aggressive CLL with t(14;19)(q32;q13). An ERIC study
- Eleonora Roncaglia,
- Enrico Gaffo,
- Giulia Calabretto,
- Moritz Fürstenau,
- Kerry A. Rogers,
- Panagiotis Baliakas,
- Chenghua Cui,
- Cecelia Miller,
- Claudia Haferlach,
- Karla Plevova,
- David Oscier,
- Zadie Davis,
- Florence Nguyen-Khac,
- Gian Matteo Rigolin,
- Anastasia Athanasiadou,
- Fanny Baran-Marszak,
- Alberto Valiente,
- Maria José Terol,
- Pau Abrisqueta,
- Blanca Espinet,
- Anna Puiggros,
- Annalisa Martines,
- Laura Bonaldi,
- Francesca Romana Mauro,
- Lydia Scarfò,
- Thomas Chatzikonstantinou,
- Eugen Tausch,
- Karl-Anton Kreuzer,
- Arnon Kater,
- Francesc Bosch,
- Michael Doubek,
- Panagiotis Panagiotidis,
- Olga Kalashnikova,
- Federica Frezzato,
- Valeria Ruocco,
- Silvia Orsi,
- Kimia Salek,
- Roberto Merlo,
- Alberto Caregari,
- Ilias Glogovitis,
- Alessandro Cellini,
- Francesco Angotzi,
- Andrea Serafin,
- Shuhua Yi,
- Barbara Eichhorst,
- Jennifer A. Woyach,
- Antonio Cuneo,
- Paolo Ghia,
- Kostas Stamatopoulos,
- Livio Trentin,
- Andrea Visentin,
- Stefania Bortoluzzi
Affiliations
- Eleonora Roncaglia
- Computational Genomics Group, Department of Surgery, Oncology and Gastroenterology, University of Padua
- Enrico Gaffo
- Department of Molecular Medicine, University of Padua
- Giulia Calabretto
- Hematology Unit, Department of Medicine, University of Padua
- Moritz Fürstenau
- Department I of Internal Medicine, University of Cologne
- Kerry A. Rogers
- The Ohio State University Comprehensive Cancer Center
- Panagiotis Baliakas
- Department of Immunology, Genetics and Pathology & Clinical Genomics Uppsala, Science for Life Laboratory, Uppsala University
- Chenghua Cui
- State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, National Clinical Research Center for Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Institutes of Health Science
- Cecelia Miller
- The Ohio State University Comprehensive Cancer Center
- Claudia Haferlach
- MLL Munich Leukemia Laboratory
- Karla Plevova
- Department of Internal Medicine, Hematology and Oncology, University Hospital Brno & Faculty of Medicine, Masaryk University
- David Oscier
- Molecular Pathology, University Hospitals Dorset, Royal Bournemouth Hospital
- Zadie Davis
- Molecular Pathology, University Hospitals Dorset, Royal Bournemouth Hospital
- Florence Nguyen-Khac
- Service d’Hématologie Biologique, Hôpital Pitié-Salpêtrière
- Gian Matteo Rigolin
- Hematology Section, Department of Medical Sciences, Arcispedale S. Anna, Azienda Ospedaliera-Universitaria, University of Ferrara
- Anastasia Athanasiadou
- Hematology Department and HCT Unit, G. Papanicolaou Hospital
- Fanny Baran-Marszak
- Laboratoire d’hématologie, Hôpital Avicenne, Assistance Publique- Hôpitaux de Paris
- Alberto Valiente
- Servicio de Genética, Hospital Universitario de Navarra
- Maria José Terol
- Servicio de Hematología y Oncología Médica, Hospital Clinico Universitario de Valencia
- Pau Abrisqueta
- Department of Hematology, Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron
- Blanca Espinet
- Molecular Cytogenetics Laboratory, Pathology Department, Translational Research on Hematological Neoplasms Group, Cancer Research Program, Hospital del Mar, Hospital del Mar Research Institute
- Anna Puiggros
- Molecular Cytogenetics Laboratory, Pathology Department, Translational Research on Hematological Neoplasms Group, Cancer Research Program, Hospital del Mar, Hospital del Mar Research Institute
- Annalisa Martines
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCSS
- Laura Bonaldi
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCSS
- Francesca Romana Mauro
- Department of Translational and Precision Medicine, Hematology Unit, ‘Sapienza’ University
- Lydia Scarfò
- Medical School, Università Vita-Salute San Raffaele
- Thomas Chatzikonstantinou
- Institute of Applied Biosciences, Center for Research and Technology Hellas
- Eugen Tausch
- Ulm University
- Karl-Anton Kreuzer
- Department I of Internal Medicine, University of Cologne
- Arnon Kater
- Department of Hematology, Cancer Center Amsterdam and Lymphoma and Myeloma Center Amsterdam
- Francesc Bosch
- Department of Hematology, Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron
- Michael Doubek
- Department of Internal Medicine, Hematology and Oncology, University Hospital Brno & Faculty of Medicine, Masaryk University
- Panagiotis Panagiotidis
- First Department of Propaedeutic, University of Athens
- Olga Kalashnikova
- Federal State Budgetary Educational Institution of Higher Education Academician I.P. Pavlov First St. Petersburg State Medical University of the Ministry of Healthcare of Russian Federation
- Federica Frezzato
- Hematology Unit, Department of Medicine, University of Padua
- Valeria Ruocco
- Hematology Unit, Department of Medicine, University of Padua
- Silvia Orsi
- Hematology Unit, Department of Medicine, University of Padua
- Kimia Salek
- Department of Molecular Medicine, University of Padua
- Roberto Merlo
- Computational Genomics Group, Department of Surgery, Oncology and Gastroenterology, University of Padua
- Alberto Caregari
- Computational Genomics Group, Department of Surgery, Oncology and Gastroenterology, University of Padua
- Ilias Glogovitis
- Department of Molecular Medicine, University of Padua
- Alessandro Cellini
- Hematology Unit, Department of Medicine, University of Padua
- Francesco Angotzi
- Hematology Unit, Department of Medicine, University of Padua
- Andrea Serafin
- Hematology Unit, Department of Medicine, University of Padua
- Shuhua Yi
- State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, National Clinical Research Center for Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Institutes of Health Science
- Barbara Eichhorst
- Department I of Internal Medicine, University of Cologne
- Jennifer A. Woyach
- The Ohio State University Comprehensive Cancer Center
- Antonio Cuneo
- Hematology Section, Department of Medical Sciences, Arcispedale S. Anna, Azienda Ospedaliera-Universitaria, University of Ferrara
- Paolo Ghia
- Medical School, Università Vita-Salute San Raffaele
- Kostas Stamatopoulos
- Institute of Applied Biosciences, Center for Research and Technology Hellas
- Livio Trentin
- Hematology Unit, Department of Medicine, University of Padua
- Andrea Visentin
- Hematology Unit, Department of Medicine, University of Padua
- Stefania Bortoluzzi
- Computational Genomics Group, Department of Surgery, Oncology and Gastroenterology, University of Padua
- DOI
- https://doi.org/10.1186/s13045-025-01725-y
- Journal volume & issue
-
Vol. 18,
no. 1
pp. 1 – 8
Abstract
Abstract In Chronic Lymphocytic Leukemia (CLL), t(14;19)(q32;q13), leading to the overexpression of BCL3, is found in ∼1% of cases and is associated with an aggressive disease. In this study, leveraging a large CLL patient cohort collected thanks to an international collaboration, we investigate for the first time the circular transcriptome (circRNAome) associated with the rare t(14;19), in comparison with CLL without t(14;19) and B cells of age-matched healthy donors. We described the circRNAs commonly dysregulated in CLL, including circCSNK1G3 and circEXOC6B(3–5), which were depleted, and circZNF609 and circLPAR3, which were overexpressed in malignant cells. Of importance, we disclosed the circRNA signature of CLL with t(14;19), formed by circRNAs with expression significantly altered specifically in link with this lesion, ectopically expressed like circCDK14(3–4), circCORO1C, circCLEC2D, and circEMB, or downregulated like circCEP70(3–6). Several of these molecules were previously shown to be dysregulated or play a role in cancer, whereas most of the signature circRNAs deserve further investigation. CLL patients with high circCORO1C and circCLEC2D expression had significantly worse clinical outcomes, with shorter time to first treatment and overall survival. This study disclosed new molecular features of the aggressive CLL subtype with t(14;19).
Keywords